AUPH Stock Aurinia Pharmaceuticals Inc.
BUY US · NasdaqGMBiotech breakout sentiment and accumulation dynamics favor a continued move higher.
Future value: $18.00 (+5.63%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Included in biotech breakout list with bullish insider sentiment.
- ▸Above 50-day MA (+3.92%)
- ▸Above 200-day MA — long-term uptrend
Is AUPH a buy right now?
Trend: AUPH is trading above the 50-day average (+3.90%), RSI 50 — neutral momentum, with a 3-month return of +13.90%.
Valuation & quality: Aurinia Pharmaceuticals Inc. trades on a trailing P/E of 7.5, forward P/E 14.6, price-to-book 3.68; fundamentals show net margin 100.8%, return on equity 66.1%, revenue growth 18.9% year on year.
Analyst consensus: 7 analysts have a mean 12-month price target of $18.00 (+5.6% vs the last close; range $16.00 – $21.00), consensus rating “buy”.
Our screen: BUY (score 3) — Biotech breakout sentiment and accumulation dynamics favor a continued move higher.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +4.60% | +3.80% | -0.40% | +10.70% | -12.30% | +8.30% | +0.50% | +5.30% |
Fundamentals
Analyst price target
Technical signals
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Sector: Healthcare · Industry: Biotechnology · Canada · 128 employees · Website
Related Biotech picks
Browse: all US stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.